Spyros Papapetropoulos
CIK 1832694 · President and CEO · last filed 2025-09-02
Spyros Papapetropoulos is a President and CEO who has filed 16 SEC Form 4 insider transactions across 4 companies since 2020. The most recent filing, for NEUP, was dated Sep 2, 2025. Across all open-market trades the lifetime net is +$49.8K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $49.1K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$49.1K
4
16
$49.8K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NEUP | President and CEO | — | $4.37 | — | $0 | 3 | 2025-09-02 |
| LPCN | Director | 21,739 | $2.26 | $49.1K | $10.2K | 6 | 2025-06-05 |
| Vigil Neuroscience, Inc. (VIGL) Delisted | Chief Medical Officer | 4,000 | $8.05 | $32.2K | $9.4K | 3 | 2022-11-22 |
| Adamas Pharmaceuticals Inc (ADMS) Delisted | Director | 0 | $8.22 | $0 | $30.2K | 4 | 2021-11-24 |
Recent Filings
16 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-09-02 | NEUP | Grant (A) | — | $0 | EDGAR |
| 2025-06-05 | LPCN | Grant (A) | — | $0 | EDGAR |
| 2025-05-19 | NEUP | Grant (A) | — | $0 | EDGAR |
| 2025-04-18 | NEUP | Grant (A) | — | $0 | EDGAR |
| 2024-06-07 | LPCN | Grant (A) | — | $0 | EDGAR |
| 2023-05-12 | LPCN | Grant (A) | — | $0 | EDGAR |
| 2022-11-28 | LPCN | Buy (P) | +21,739 | $10.2K | EDGAR |
| 2022-11-22 | Vigil Neuroscience, Inc. (VIGL) Delisted | Mixed | — | -$3.6K | EDGAR |
| 2022-06-10 | LPCN | Grant (A) | — | $0 | EDGAR |
| 2022-05-04 | Vigil Neuroscience, Inc. (VIGL) Delisted | Buy (P) | +4,000 | $13.6K | EDGAR |